2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2487

Comparison the Long-Term Clinical Outcomes between Non Anti-TNF Versus Anti-TNF in RA Patients Who Failed to a First Anti-TNF
Abstract Number: 1132

Compensated Polarized Microscopy for Crystal Identification Shows High Reliability Among Multiple Observers
Abstract Number: 682

Complement Activation in Peripheral Blood in Relation to Lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights from Clinical Laboratory Evaluations
Abstract Number: 1671

Complement C4 Gene Copy Number Variations Bestow Large Ranges of Serum C4 Protein Levels in Chinese Patients with Systemic Lupus Erythematosus (SLE) and Contribute to Organ and Cardiovascular Damages over Time
Abstract Number: 568

Complement Consumption As a Predictor of Pulmonary Manifestation in Patients with Primary Sjögren’s Syndrome: Results from a Unicentric Observational Study
Abstract Number: 2829

Complete Epigenetic Landscape of Rheumatoid Arthritis Fibroblast-like Synoviocytes Reveals Unanticipated Critical Pathogenic Pathways
Abstract Number: 2582

Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
Abstract Number: 2028

Compliance with Pneumococcal Vaccination in Rheumatic Disease Patients on Immunosuppressive Medications
Abstract Number: 1018

Comprehensive Identification of Differentially Methylated Regions Associated with Systemic Sclerosis in Dermal Fibroblasts from African-American Patients
Abstract Number: 561

Comprehensive Immuno-Phenotyping of Follicular Helper T Cell and B Cell Subpopulations in Primary Sjögren’s Syndrome
Abstract Number: 1342

Comprehensive Provider Judgment Outweighs Disease Activity Measures in the Decision to Not Escalate Therapy in Patients with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 309

Compression Assisted Arthrocentesis and Intraarticular Injection
Abstract Number: 2053

Computed Tomography Dependent Diagnosis of Crowned Dens Syndrome; A Cervical Manifestation of Patients with Calcium Pyrophosphate Dihydrate Crystal Deposition Disease
Abstract Number: 201

Computer Learning (artificial intelligence) to Create a Computer-Based Triage Tool Classifying Referrals As Inflammatory or Non-Inflammatory Requiring Only Patient Reported Information
Abstract Number: 546

Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].